Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

NCT03332355 is registered in ClinicalTrials.gov with Vanquish Oncology, Inc. as lead sponsor.

NCT NCT03332355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03332355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Lead sponsor
Vanquish Oncology, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 1, 2017
Completion date
December 31, 2021
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma multiforme